Abstract
This article describes the discovery and development of the first highly selective, small molecule antagonist of the muscarinic acetylcholine receptor subtype I (mAChR1 or M1). An M1 functional, cell-based, calcium-mobilization assay identified three distinct chemical series with initial selectivity for M1 versus M4. An iterative parallel synthesis approach was employed to optimize all three series in parallel, which led to the development of novel microwave-assisted chemistry and provided important take home lessons for probe development projects. Ultimately, this effort produced VU0255035, a potent (IC50 = 130 nM) and selective ( > 75-fold vs. M2-M5 and > 10 iM vs. a panel of 75 GPCRs, ion channels and transporters) small molecule M1 antagonist. Further profiling demonstrated that VU0255035 was centrally penetrant (BrainAUC/PlasmaAUC of 0.48) and active in vivo, rendering it acceptable as both an in vitro and in vivo MLSCN/ MLPCN probe molecule for studying and dissecting M1 function.
Keywords: Muscarinic, acetylcholine, mAChR, M1, antagonist
Current Topics in Medicinal Chemistry
Title: Discovery and Development of a Potent and Highly Selective Small Molecule Muscarinic Acetylcholine Receptor Subtype I (mAChR 1 or M1) Antagonist In Vitro and In Vivo Probe
Volume: 9 Issue: 13
Author(s): Satyawan Jadhav, Craig W. Lindsley, P. Jeffrey Conn, Fang Zheng, Matthew M. Mock, Colleen M. Niswender, Joy Marlo, Carrie K. Jones, Leslie A. Aldrich, C. David Weaver, Matthew M. Mulder, J. Phillip Kennedy, Natalia T. Nalywajko, Richard Williams, Thomas M. Bridges, L. Michelle Lewis and Douglas J. Sheffler
Affiliation:
Keywords: Muscarinic, acetylcholine, mAChR, M1, antagonist
Abstract: This article describes the discovery and development of the first highly selective, small molecule antagonist of the muscarinic acetylcholine receptor subtype I (mAChR1 or M1). An M1 functional, cell-based, calcium-mobilization assay identified three distinct chemical series with initial selectivity for M1 versus M4. An iterative parallel synthesis approach was employed to optimize all three series in parallel, which led to the development of novel microwave-assisted chemistry and provided important take home lessons for probe development projects. Ultimately, this effort produced VU0255035, a potent (IC50 = 130 nM) and selective ( > 75-fold vs. M2-M5 and > 10 iM vs. a panel of 75 GPCRs, ion channels and transporters) small molecule M1 antagonist. Further profiling demonstrated that VU0255035 was centrally penetrant (BrainAUC/PlasmaAUC of 0.48) and active in vivo, rendering it acceptable as both an in vitro and in vivo MLSCN/ MLPCN probe molecule for studying and dissecting M1 function.
Export Options
About this article
Cite this article as:
Jadhav Satyawan, Lindsley W. Craig, Conn Jeffrey P., Zheng Fang, Mock M. Matthew, Niswender M. Colleen, Marlo Joy, Jones K. Carrie, Aldrich A. Leslie, Weaver David C., Mulder M. Matthew, Kennedy Phillip J., Nalywajko T. Natalia, Williams Richard, Bridges M. Thomas, Lewis Michelle L. and Sheffler J. Douglas, Discovery and Development of a Potent and Highly Selective Small Molecule Muscarinic Acetylcholine Receptor Subtype I (mAChR 1 or M1) Antagonist In Vitro and In Vivo Probe, Current Topics in Medicinal Chemistry 2009; 9 (13) . https://dx.doi.org/10.2174/156802609789753635
DOI https://dx.doi.org/10.2174/156802609789753635 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Measurement of Extravascular Lung Water in Critically Ill Patients
Current Respiratory Medicine Reviews Drug Re-purposing from SARS-CoV Led the Identification of Potential Candidate Drug Target and Alternate Drug Molecules Against SARSCoV- 2
Letters in Drug Design & Discovery Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art
Current Cardiology Reviews Luminescent G-quadruplex Probes
Current Pharmaceutical Design Target Practice: Aiming at Satellite Repeats with DNA Minor Groove Binders
Current Medicinal Chemistry - Anti-Cancer Agents Mucormycosis in India: Pathophysiology and Perspectives on Treatment and Management
Infectious Disorders - Drug Targets Resveratrol in Cancer Therapy: From Stimulation of Genomic Stability to Adjuvant Cancer Therapy: A Comprehensive Review
Current Topics in Medicinal Chemistry Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Preliminary Screening of Novel A- and D-Ring Modified Steroids as Aromatase Inhibitors
Letters in Drug Design & Discovery Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry Nf-κb: A Target for Synchronizing the Functioning Nervous Tissue Progenitors of Different Types in Alzheimer's Disease
Current Molecular Pharmacology Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges
Current Medicinal Chemistry A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews MraY Inhibitors as Novel Antibacterial Agents
Current Topics in Medicinal Chemistry COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies
Current Pharmaceutical Design Fluorinated Natural Products with Clinical Significance
Current Topics in Medicinal Chemistry Cysteinyl Leukotriene Receptor Antagonists and Thromboxane Synthase Inhibitors: New Targets to Treat Asthma
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents